AWD-12-281 (inhaled) elbion/GlaxoSmithKline

Current Opinion in Investigational Drugs

Volumn 6, Issue 11, 2005, Pages 1149-1158

  Gutke, Hans Jürgen ^a   Guse, Jan Hinrich ^a   Khobzaoui, Moussa ^a   Renukappa Gutke, Thejavathi ^a   Burnet, Michael ^a  

^a Synovo GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AWD 12 343; AWD 12 353; BECLOMETASONE; CC 10004; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; ELB 353; GLUCOCORTICOID; LOTEPREDNOL ETABONATE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PLACEBO; ROFLUMILAST; ROLIPRAM; UNCLASSIFIED DRUG; ZARDAVERINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; IC 50; MAXIMUM TOLERATED DOSE; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; AMIDES; AMINOPYRIDINES; ANIMALS; BENZAMIDES; CLINICAL TRIALS; CYCLOPROPANES; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; INFLAMMATION; LIPOPOLYSACCHARIDES; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28244488701     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 30771 Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, Livi GP J BIOL CHEM 1992 267 3 1798-1804
2. 213439 Glucocorticosteroids, old and new: Biological function and use in the treatment of asthma. Mobley JL, Chin JE, Richards IM EXPERT OPIN INVEST DRUGS 1996 5 7 871-884
3. 3H]rolipram binding activity and their relationship to emetic behavior in ferret. Duplantier AJ, Biggers MS, Chambers RJ, Chambers RJ, Chang JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H et al J MED CHEM 1996 39 1 120-125
4. 276922 PDE 4 inhibitors: The use of molecular cloning in the design and development of novel drugs. Hughes B, Owens R, Perry M, Warrellow G, Allen R DRUG DISCOV TODAY 1997 2 3 89-101
5. 304539 Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Torphy TJ AM J RESPIR CRIT CARE MED 1998 157 2 351-370
6. 304642 Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Souness JE, Rao S CELL SIGNAL 1997 9 3-4 227-236
7. 316578 SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ J PHARMACOL EXP THER 1998 287 2 705-711
8. 332907 AWD 12-281, a new PDE4 inhibitor - created by ligand based drug design. Hofgen N, Polymeropoulos E, Egerland U, Poppe H, Marx D, Kronbach T, Szelenyi S MEDIATORS INFLAMM 1999 8 Suppl 1 P-06-5
9. 334829 Effect of the PDE-4 inhibitors RPR-73401 and AWD-12-281 on human monocytes. Nieber K, Scultz S, Donath S, Hauschildt S FUNDAM CLIN PHARMACOL 1999 13 Suppl 1 PM1187
10. 334892 Tosk Inc licenses key gene therapy, neuroscience, and stem cell technologies from Stanford University. Tosk Inc PRESS RELEASE 1999 August 02
11. 372149 AWD 12-343, a new orally active PDE4 inhibitor- synthesis and comparison with SB 207499, rolipram and AWD 12-281. Hofgen N, Egerland U, Poppe H, Kusters S, Kronbach T, Szelenyi S NATL MED CHEM SYMP 2000 27 Abs 19
12. 381232 Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, Hoffman CR, Luther MA BIOCHEMISTRY 1997 36 46 14250-14261
13. 381233 Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT SCIENCE 2000 288 5472 1822-1825
14. 3H]rolipram binding. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ BIOCHEM PHARMACOL 1996 51 7 949-956
15. 383842 AWD-12-343, a new orally active PDE4 inhibitor-synthesis and comparison with SB 207499, rolipram AWD 12-281. Hofgen N, Egerland U, Poppe H, Kusters S, Kronbach T, Szelenyi S INT SYMP MED CHEM 2000 16 Abs PA79
16. 402539 Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Hatzelmann A, Schudt C J PHARMACOL EXP THER 2001 297 1 267-279
17. 412899 In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R J PHARMACOL EXP THER 2001 297 1 280-290
18. 417192 Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. Ezeamuzie CI EUR J PHARMACOL 2001 417 1-2 11-18
19. 417248 A peptidic binding site model for PDE 4 inhibitors. Polymeropoulos EE, Hofgen N QUANT STRUCT ACT RELATSH 1999 18 6 543-547
20. 456304 AWD 12-281: Antiasthmatic/antiinflammatory phosphodiesterase 4 inhibitor. Kuss H, Hoefgen N, Egerland U, Heer S, Marx D, Szelenyi I, Schupke H, Gasparic A, Olbrich M, Hempel R, Hartenhauer H et al DRUGS FUTURE 2002 27 2 111-116
21. 457183 Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. Tenor H, Schudt C. PHOSPHODIESTERASE INHIBITORS (EDS: SCHUDT C, DENT G, RABE KF) Academic Press, London, UK 1996 21-40
22. 457611 GlaxoSmithKline and elbion to collaborate on development and commercialisation of AWD12-281, a new PDE-IV inhibitor for rhinitis, asthma and COPD. GlaxoSmithKline plc, elbion AG PRESS RELEASE 2002
23. 467734 Product development pipeline - October 2002. GlaxoSmithKline plc COMPANY PUBLICATION 2002 October 23
24. 467753 GSK 3Q02 results show strong underlying growth. Pendrill A, Parry G, Lee C ABN AMRO 2002 October 23
25. 480252 Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis. Baumer W, Gorr G, Hoppmann J, Ehinger AM, Ehinger B, Kietzmann M EUR J PHARMACOL 2002 446 1-3 195-200
26. 480322 Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Marx D, Tassabehji M, Heer S, Huttenbrink KB, Szelenyi I PULM PHARMACOL THER 2002 15 1 7-15
27. 480331 Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D CELL SIGNAL 2001 13 4 287-297
28. i and cytokine secretion in human monocytes. Eschke D, Loos S, Hauschildt S, Nieber K NAUYN SCHMIEDEBERGS ARCH PHARMACOL 2000 361 4 Abs 326
29. 480517 Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Burnouf C, Pruniaux MP CURR PHARM DESIGN 2002 8 14 1255-1296
30. 488868 Small Molecule Therapeutic Approaches to Asthma and Other Respiratory Diseases - Cell Signalling Targets. Schafer P SMI CONF - ASTHMA THER 2003 April 30 - May 01
31. 504644 GSK Ariflo long-term efficacy trials needed for COPD approval - FDA Cmte. FDC REP PINK SHEET 2003 65 36 24
32. 510678 GlaxoSmithKline receives FDA approvable letter for Ariflo (cilomilast) tablets 15 mg. GlaxoSmithKline plc PRESS RELEASE 2003 October 28
33. 515870 Drug Development Pipeline. GlaxoSmithKline plc COMPANY WORLD WIDE WEB SITE 2003 December 03
34. 516398 GlaxoSmithKline Research and Development day. GlaxoSmithKline plc COMPANY PRESENTATION 2003 December 03
35. 527734 CC-10004: A novel PDE4 inhibitor with an improved therapeutic index. Schafer P SMI CONF - CHRON OBSTRUCT PULM DISORDERS 2004 March 10-11
36. 550581 In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl) -5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C J PHARMACOL EXP THER 2003 307 1 373-385
37. 550583 Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl) -5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. Draheim R, Egerland U, Rundfeldt C J PHARMACOL EXP THER 2004 308 2 555-563
38. 550586 AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. Baumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M J PHARM PHARMACOL 2003 55 8 1107-1114
39. 562362 Inflammation Research Association - 12th International Conference (Part I) - Overnight Report, Bolton Landing, NY, USA. Keeping KM IDDB MEETING REPORT 2004 October 3-7
40. 562490 Projects. elbion AG COMPANY WOLD WIDE WEB SITE 2004 October 05
41. 563994 Sterolides - a new class of potent anti-inflammatory compounds. Mercep M, Tomaskovi L, Hrva B, Markovi S, Stegi OS, Poljak V, KOmac M, Sijan G, Matijas M, Stani B, Stipani S et al INFLAMM RES 2004 53 Suppl 3 Abs 125
42. 571646 Phosphodiesterases in Drug Discovery and Development - SRI's Second Annual Conference, Philadelphia, PA, USA. Rotella DJ IDDB MEETING REPORT 2004 November 08-09
43. 578233 AWD-281, a new PDE4 inhibitor, suppresses allergen-induced early phase bronchoconstriction in sensitized guinea pigs. Kuss H, Hoefgen N, Rundfelt C 2003 22 Suppl 45 P741
44. 582570 Pipeline Overview. elbion AG COMPANY WOLD WIDE WEBSITE 2005 February 01
45. 583746 Structural basis for the activity of drugs that inhibit phosphodiesterases. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR et al STRUCTURE 2004 12 12 2233-2247
46. 583773 Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ LANCET 2005 365 9454 167-175
47. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC J CLIN INVEST 2002 110 7 1045-1052
48. 588333 Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869. DRUGS R&D 2004 5 3 176-181
49. 590470 Crystal structure of phosphodiesterase 4D and inhibitor complex (1). Lee ME, Markowitz J, Lee JO, Lee H FEBS LETT 2002 530 1-3 53-58
50. 592024 The potential of PDE4 inhibitors in respiratory disease. Spina D CURR DRUG TARGETS INFLAMM ALLERGY 2004 3 3 231-236
51. 592494 Searching for a reliable orientation of ligands in their binding site: Comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors. Gratteri P, Bonaccini C, Melani F J MED CHEM 2005 48 5 1657-1665
52. 612889 elbion AG Increases Series A Financing to ε 35 Million. elbion AG PRESS RELEASE 2005 May 24
53. 612977 Inhaled PDE4 Inhibitors: Opportunity to Improve the Therapeutic Window. Rundfelt C, Hoefgen N, Kuss H, Kronbach T SRI - PHOSPHODIESTERASES DRUG DISCOVERY DEV 2004 November http://www.elbion.de/pdf/Rundfeldt-SRI-Conf2004.pdf
54. 2A agonist inhibit MIPβ release from human peripheral blood mononuclear cells (PBMCs) and neutrophils. Bell CJ, Barnard A, Mansfield F, Salmon G, Sims G, Banner KH, Trevethick MA, Yeadon M AM J RESPIR CARE MED 2004 169 A805
55. 618779 Inflammation 2005 - Seventh World Congress (Part II) - Overnight Report, Melbourne, Australia, 20-24 August 2005. Enefer S IDDB MEETING REPORT 2005 August 20-24
56. 14C]ciclesonide after oral and intravenous administration to healthy subjects. Nave R, Bethke TD, van Marle SP, Zech K CLIN PHARMACOKINET 2004 43 7 479-486
57. 622878 Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD LANCET 2005 366 9485 563-571
58. 623221 Notiz über einige derivate der [5-benzyloxy-indolyl-(3)]-glyoxylsäure. Lipp M, Dallacker F, Steinheuer I CHEM BER 1958 91 242-243
59. 624643 The constitution of yohimbine and related alkaloids. Part XII. Some unsuccessful synthetic approaches to yohimbine and alstoniline. Prasad KB, Swan GA J CHEM SOC 1958 2045-2051
60. 625264 Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R EUR J RESPIR DIS 1982 122 Suppl 86-95
61. 625432 Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG J ALLERGY CLIN IMMUNOL 2005 116 2 292-298
62. 625446 Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Richter W, Jin SL, Conti M BIOCHEM J 2005 388 3 803-811